Psoriasis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Psoriasis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Psoriasis Treatment Market

The global psoriasis treatment market size was valued at USD 26.37 billion in 2022, and the market is now projected to grow from USD 28.61 billion in 2023 to USD 51.48 billion by 2030, exhibiting a CAGR of 8.8% during the forecast period of 2023-2030.

The pandemic has had a positive effect on the market with the growth rate much higher in 2020. The market reached a rise of 11. 1% – this level is significantly lower than the CAGR of the 2019. The major cause of growth was an increase in the revenues of the key players. The treatment for psoriasis has gained higher demand. The amount of the investment in the research and the development of the new drugs also rose. Several medical research studies had proved the connection between COVID-19 and this autoimmune disorder, Numerous of the patients suffered from the symptoms of psoriasis., which boosted the psoriasis treatment market growth.

The biologics or the biological therapy is one of the topmost psoriasis treatment options. A lot of big companies have noted the new product launch as the best way to achieve market expansion. Moreover, the market players are concentrating on the forging of strategic collaborations and mergers, which have produced a number of new products. These factors have led the company to the oral route of administration and it has succeeded to the opening of the company's product line which has helped the company to expand further. This led to the substantial increase in psoriasis treatment market share.

Patients want to get efficient ways to get psoriasis treatment. The biologics have changed the treatment of this condition by being new and aiming to the specific points in which the inflammatory pathway is, and thereby causes the fewer of the side effects. Hence, the major contributors have changed their attention from the development of other drugs to that of the biologics. Creating biologics guarantees that the procedure of obtaining a permit for the new drug is much simpler.

Comprehensive Analysis of Psoriasis Treatment Market

The psoriasis treatment market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated By Drug Class Analysis, By Type Analysis, By Route of Administration Analysis and By Distribution Channel Analysis. Base on the drug class, the market is now classified into TNF inhibitors, interleukin inhibitors, and others. The global market can be sectioned into the type of plaque psoriasis, psoriatic arthritis, and others. The plaque psoriasis group became the leader in the psoriasis treatment market share as it was the most prevalent type of psoriasis, the cases of which were 80-90% of the total. Based on administration, the market is labeled into oral, parenteral/systemic, and topical. Based on distribution channels, the marketplace is segmented into medical institution pharmacies, retail pharmacies, and online pharmacies.

The North American market size was estimated at USD 11.21 billion by 2022. The increasing burden of the condition in the region and increasing infrastructure in the general public is expected to provide an effective treatment to overcome condition the demand for the solution has increased. This dominance is attributed to increased adoption of advanced pharmaceutical remedies, improved R&D funding with the aid of key gamers inside the industry in clinical trials for the remedy of psoriasis, and healthcare initiatives extended length of prevention.

AbbVie Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc. (U.S.), LEO Pharma A/S (Denmark), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), Evelo Biosciences, Inc. (U.S.), UCB S.A. (Belgium) and Sun Pharmaceutical Industries Ltd. (India) are key players in the electronic signature and digital security market. These firms occupy the central place in the healthcare industry as they contribute to manufacturing growth and define high standards . These pioneers appear to be the propelling units for technological advancement and a competitive market that evolves with time and customer trust. The dominance is due to their powerful distribution networks and their concentration on the mergers and partnerships with the big-name dermatology or immunology organizations.

In September 2022, Bristol Myers Squibb received the FDA popularity of Sotyktu, an oral, allosteric tyrosine kinase 2-inhibitor for treating adults tormented by moderate-to-severe plaque psoriasis.

Segmentation Table

Attribute Details

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 8.8% from 2023-2030

Unit Value (USD billion)

Segmentation By Drug Class, Type, Route of Administration, Distribution Channel, and Region

By Drug Class TNF Inhibitors

Interleukins Inhibitors

Others

By Type Plaque Psoriasis

Psoriatic Arthritis

Others

By Route of Administration Oral

Parenteral/Systemic

Topical

By Distribution Channel Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography North America (By Drug Class, Type, Route of Administration, Distribution Channel, and Country)

U.S. (By Type)

Canada (By Type)

Europe (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)

- U.K. (By Type)

- Germany (By Type)

- France (By Type)

- Italy (By Type)

- Spain (By Type)

- Scandinavia (By Type)

- Rest of Europe (By Type)

Asia Pacific (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)

- Japan (By Type)

- China (By Type)

- India (By Type)

- Australia & New Zealand (By Type)

- Rest of Asia Pacific (By Type)

Latin America (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)

- Brazil (By Type)

- Mexico (By Type)

- Rest of Latin America (By Type)

Middle East & Africa (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)

- GCC (By Type)

- South Africa (By Type)

- Rest of Middle East & Africa (By Type)


Please Note: It will take 2-3 business days to complete the report upon order confirmation.